ALTEOGEN Inc. (196170.KQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Soon-Jae Park Ph.D. | Chief Executive Officer | -- | -- | 1954 |
| Mr. Hang Yeon Kim | CFO & Executive VP | -- | -- | 1965 |
| Mr. Sang Woo Kang | Senior Vice President of Management Support Group | -- | -- | -- |
| Dr. Tae-Yon Chun J.D., Ph.D. | Executive VP & Corporate Alliance Officer | -- | -- | 1965 |
| Mr. Kyuwan Kim | Senior VP & Head of New Drug Development | -- | -- | -- |
| Mr. Vivek B. Shenoy M.B.A., Ph.D. | Chief Business Development Officer | -- | -- | -- |
ALTEOGEN Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Corporate Governance
Upcoming Events
May 16, 2025 at 10:59 AM UTC - May 19, 2025 at 12:00 PM UTC
ALTEOGEN Inc. Earnings Date
Recent Events
Recent Events Information Not Available